The integration of ICIs, such as PD-1/PD-L1 inhibitors, with BRAF/MEK inhibitors represents a transformative approach in melanoma treatment (Gide et al., 2018; Carlino et al., 2021). The gene discussed is MAP2K7; the disease is melanoma.